Rpf蛋白结构域的生物学及免疫学特性的初步研究
|
摘要
结核病(Tuberculosis,TB)是由结核分枝杆菌(Mycobacterium tuberculosis,MTB)所致的以呼吸系统感染为主的慢性传染病,也是现今全世界范围内最重要的致病和致死因素之一。据WHO估计,目前全世界约有1/3人口处于MTB感染状态,我国TB患者数量居世界第二位,感染人数已达4亿。这部分人中只有10%可能最终发展成为活动性TB,而绝大多数为隐性感染,感染的细菌以休眠菌的形式存在。这种休眠菌耐药性极强,可在体内长期存在,常规方法难于分离培养。卡介苗(Bacille Calmette-Guerin,BCG)是MTB的减毒株,是目前唯一用于TB预防的疫苗,但其对隐性感染者无效,还存在保护期短,免疫应答较弱等缺陷。因此,研究MTB的致病及免疫机制,研制更为有效的诊断、治疗和预防MTB感染,特别是针对隐性感染的新方法、新措施及新疫苗等具有重要意义。
近年来研究发现,在MTB休眠菌的复苏过程中,MTB分泌的5种促进复活因子(Resuscitation promoting factor,Rpf)起了重要作用,分别为Rv0867c(RpfA),Rv1009(RpfB),Rv1884c(RpfC),Rv2389c(RpfD)和Rv2450c(RpfE)。Rpf最早在藤黄微球菌(Micrococcus luteus,M.luteus)中发现。通过同源性分析发现,Rpf存在于多种富含G+C的革兰阳性细菌中,其基因编码的蛋白均具有Rpf样结构域。在研究中发现,Rpf蛋白的结构域与完整Rpf蛋白具有一致的生物学特性。对Rpf家族的研究还发现,Rpf样蛋白不仅与细菌的增殖有关,还可能是宿主免疫系统识别的靶抗原。
在本研究中,我们分别克隆、表达和纯化了藤黄微球菌Rpf蛋白、Rpf结构域蛋白、RpfB结构域蛋白;制备了抗藤黄微球菌Rpf结构域和抗RpfB结构域的单克隆抗体(monoclonal antibody,MAb);研究了藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白的生物学功能和免疫学特性。评价其用于MTB分离培养添加剂、相关抗原检测方法建立及TB新型疫苗研制的可能性。实验目的:利用大肠杆菌表达系统表达并纯化藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白;制备抗藤黄微球菌Rpf结构域、抗RpfB结构域的MAb;进一步研究其生物学功能和免疫学特性。
实验方法和结果:
1.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的克隆、表达与纯化采用PCR方法分别从藤黄微球菌和MTB H37Rv的基因组中分别扩增出相应大小的藤黄微球菌Rpf、Rpf结构域和RpfB结构域目的基因片段,并分别克隆入pUC-19载体中测序,结果与GenBank报道的完全一致。将目的基因分别克隆人pProEX HTb表达载体中,酶切鉴定后,分别在E.coli中由IPTG诱导表达目的蛋白。经SDS-PAGE分析,表达的3种目的蛋白与预期分子量一致;Western-blot分析表明3种融合6×His的目的蛋白均可与抗6×His MAb特异反应。3种目的蛋白均以包涵体的形式表达,用亲和色谱法在变性条件下分别纯化3种目的蛋白。
2.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的生物学功能研究
2.1抗藤黄微球菌Rpf结构域、抗RpfB结构域MAb的制备及鉴定
用藤黄微球菌Rpf结构域蛋白分别免疫BALB/c小鼠,进行细胞融合,获得了3株能稳定分泌抗藤黄微球菌Rpf结构域MAb的杂交瘤细胞系,分别命名为F3D10、G10D5、G6C8,其中F3D10、G10D5为IgG1亚类,G6C8为IgM亚类,其相对亲和力为F3D10>G6C8>G10D5;用RpfB结构域蛋白免疫BALB/c小鼠,进行细胞融合,获得了3株能稳定分泌抗RpfB结构域MAb的杂交瘤细胞系,分别命名为D3A5、B8G11、A9C8,其中D3A5、B8G11为IgG1亚类,A9C8为IgM亚类,其相对亲和力为A9C8>D3A5>B8G11。
分别构建了pcDNA3.1(-)-Rpf结构域及pcDNA3.1(-)-RpfB结构域真核表达载体,转染COS-7细胞,用间接免疫荧光法检测表明藤黄微球菌Rpf结构域蛋白和RpfB结构域蛋白在COS-7细胞中有表达,也间接验证了MAb的特异性。
2.2抗藤黄微球菌Rpf结构域及抗RpfB结构域MAb的交叉实验。分别用藤黄微球菌Rpf、Rpf结构域、RpfB结构域、RpfA(本实验室纯化的MTB RpfA蛋白,质粒为国外Mike Young教授馈赠)及H37Ra作为抗原与制备的两种MAb反应,结果显示:两种抗结构域MAb均可以与以上蛋白和H37Ra菌株发生反应。
2.3藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白促藤黄微球菌及MTB H37Ra休眠菌的复苏和生长作用
取藤黄微球菌和MTB H37Ra的休眠菌适当稀释后,随机分为3组。每组分别加入不同稀释浓度的纯化蛋白及相应的抗结构域MAb,取不同时间点的培养液测OD600值,绘制生长曲线。结果显示:当藤黄微球菌Rpf和Rpf结构域浓度均为100pmol/L时,刺激藤黄微球菌复苏和生长作用明显,当藤黄微球菌Rpf浓度为10pmol/L、Rpf结构域浓度为100pmol/L时,刺激MTB H37Ra复苏和生长作用明显,而且这种刺激作用在加入了1:600的抗藤黄微球菌Rpf结构域MAb后明显被抑制;当RpfB结构域浓度为1000pmol/L时,刺激藤黄微球菌复苏和生长作用明显,当RpfB结构域浓度为500pmol/L时,刺激MTB H37Ra复苏和生长作用明显,而且这种刺激作用在加入了1:1000的抗RpfB结构域MAb后明显被抑制。
3.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的免疫学特性研究
采用皮下包埋的方法,分别将藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白滴到硝酸纤维素膜小块上,免疫小鼠3次,每次间隔2周,同时设BCG免疫组和生理盐水对照组。用ELISA方法检测免疫小鼠血清中的特异性抗体平均滴度。结果显示:藤黄微球菌Rpf蛋白免疫组最高抗体效价为1:12800,藤黄微球菌Rpf结构域蛋白免疫组最高抗体效价为1:4800,RpfB结构域蛋白免疫组最高抗体效价为1:6400。
为了检测蛋白免疫小鼠引起的细胞免疫应答,最后一次免疫完成两周后,分离各免疫组小鼠脾淋巴细胞,在体外经PPD刺激后,MTT法检测淋巴细胞增殖反应,藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白免疫小鼠后的刺激指数分别为:2.86±0.12,2.10±0.09,2.40±0.11,明显高于生理盐水对照组(0.90±0.21)(P<0.01),但不及BCG免疫组(3.50±0.23)(P<0.05)。藤黄微球菌Rpf蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1528±36ng/L,485±13ng/L和302±14ng/L;藤黄微球菌Rpf结构域蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1126±36ng/L,368±13ng/L和289±14ng/L;RpfB结构域蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1432±30ng/L,503±11ng/L和311±11ng/L;BCG免疫组诱导产生的IFN-γ,IL-10和IL-12平均水平分别为2022±38ng/L,578±13ng/L和400±10ng/L;生理盐水对照组IFN-γ,IL-10和IL-12水平分别为256±6ng/L,76±3ng/L和56±4ng/L。从结果可以看出,3种蛋白免疫小鼠后诱导产生的细胞因子水平明显高于生理盐水对照组(p<0.01),但不及BCG免疫组(p<0.05)。
免疫完成后第四周,用105CFU MTB H37Rv毒株经尾静脉攻击上述各免疫组小鼠,计数脾脏细菌负荷数。与生理盐水对照组相比,藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白免疫组小鼠对H37Rv毒株攻击后MTB在脾脏中的增殖均有显著抑制作用(差值分别为1.89 log10、1.61 log10和1.78 log10)(p<0.05),但不如BCG免疫组(差值为2.83 log10)(p<0.05)。
结论:藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白均具有促进藤黄微球菌和MTB休眠菌复苏和生长的作用,有望用于临床标本分离培养的添加剂,促进MTB休眠菌的复苏和生长,从而提高隐性感染者的检出率;抗两种结构域的MAb不仅可以明显抑制3种蛋白的促复苏和生长作用,而且可以特异性的识别多种Rpf蛋白及其结构域,据此,有可能建立MTB相关抗原的检测方法;3种蛋白免疫动物后诱导产生的特异性免疫应答,对MTB毒株的攻击具有一定的保护力,它们有可能用于TB新型疫苗的研制。
Tuberculosis (TB) is a chronic respiratory infectious disease caused by the pathogen Mycobacterium tuberculosis (MTB). It has been one of the most important contributory and mortiferous factors in the world. It is estimated by WHO that one-third of the world population are infected with MTB. In China, the number of TB patients was the second in the world, approximately 400 million people infected. 10% of these people will develop to activity TB, and the most of infected MTB exist in condition of dormant infection. This dormant MTB has strong drug resistance, it can exist in vivo for a long time, and it’s difficult to isolate and cultivate. The current vaccine against MTB, M. bovis Bacillus Calmette-Guérin(BCG)has many problems such as ineffective to subclinical infection,short period of protect and low immune response. Current preventive measures and diagnosis methods have no effect on MTB dormant. So it is great significant for studying new diagnosis reagents, therapy methods and vaccines to prevent TB, especially for dormant infection.
Recent studies showed that the resuscitation promoting factor(Rpf) which secreted by MTB played a important role in promoting the resuscitation and growth of dormant mycobacterium, Rv0867c(RpfA),Rv1009(RpfB),Rv1884c(RpfC),Rv2389c(RpfD)and Rv2450c(RpfE). Rpf was first discovered in Micrococcus luteus(M.luteus). Homology analysis suggests that Rpf-like protein widely distribute among high G+C Gram-positive bacteria. It has been found the domain of Rpf has the same biological characteristics as Rpf-like protein. It also has been demonstrated that Rpf-like protein can not only stimulate the resuscitation of stationary-phase mycobacterial, including M. bovis BCG and MTB, but also a target antigen of immune system of host. In this study, we cloned, expressed and purified M.luteus Rpf protein, M.luteus Rpf domain protein and RpfB domain protein, generated MAb of M.luteus Rpf domain and RpfB domain. Furthermore, we studied the biological function and immunological characteristics of them, in order to evaluate the possibility of using them to rapidly isolate and cultivate MTB, detect related antigen, and become candidate vaccines.
AIM: To express and purify M.luteus Rpf protein, Rpf domain and RpfB domain.To generate MAb of M.luteus Rpf domain and RpfB domain .To study the biological and immunological properties of M.luteus Rpf, Rpf domain and RpfB domain.
METHODS AND RESULTS:
1. Cloning, expression and purification of M.luteus Rpf protein, Rpf domain and RpfB domain
The genes of M.luteus Rpf, Rpf domain and RpfB domain were amplified respectively from genome of M.luteus and MTB H37Rv strain by using polymerase chain reaction(PCR). Inserted the PCR product into pUC-19 vector accordingly and sequenced. The DNA sequence of M.luteus Rpf, Rpf domain and RpfB domain were identical with that published by GenBank. After sequencing was confirmed, Subcloned the three right sequenced genes into pPRO-EXHT prokaryotic expression vector . The recombinant clones were screened restriction enzyme analysis and transformed into E.coli DH5αstrain and induced with IPTG. The analysis of SDS-PAGE showed that there were specific protein expressions at the corresponding positions as we anticipated. The three proteins were further identified by Western-blot using anti-6×His MAb.Purified theproteins by Ni-NTA purification system under denaturing conditions.
2. Biological Activity Of M.luteus Rpf protein, Rpf domain and RpfB domain
2.1 Construction and identification of MAbs to M.luteus Rpf domain and RpfB domain
We obtained 3 hybridoma cell strains which could stablely secrete antibodies adainst M.luteus, named F3D10,G10D5 and G6C8 from BALB/c mice immunized with. The subclass of F3D10 and G10D5 is IgG1,while the subclass of G6C8 is IgM. The relative affinity of the MAbs are different and the sequence is A9C8>D3A5>B8G11.We also obtained 3 hybridoma cell strains which could stablely secrete antibodies adainst RpfB domain ,named D3A5,B8G11 and A9C8. The subclass of D3A5 and B8G11 is IgG1,while the subclass of A9C8 is IgM. The relative affinity sequence of the MAbs is A9C8>D3A5>B8G11.
In order to identify the specificity of the MAb, we constructed eukaryotic expression vector pcDNA3.1(-)-Rpf domain and pcDNA3.1 (-)-RpfB domain, and expressed in COS-7 cells. The specificity of the MAb was confirmed with indirect immunofluorescence.
2.2 Cross test of anti-M.luteus Rpf domain and anti-RpfB domain.
Cross test of the two constructed MAbs were detected by ELISA, using Rpf, Rpf domain, RpfB domain, and other Rpf proteins of MTB as antigen to invest culture plate respectively and the two constructed MAbs to be the first antibody. The results showed both MAbs have reaction with all above proteins.
2.3 The promotive action of resuscitation and growth of M.luteus Rpf, Rpf domain and RpfB domain on M.luteus and MTB
H37Ra and M.luteus dormant strains were at a suitable dilution using culture medium, and then divided into 3 groups randomly. Different concentration proteins were added to each group respectively. Taken 200μl from each group at different time to detected the OD600. The results showed that Rpf protein and Rpf domain could significantly stimulate the growth of M.luteus at concentration of 100pmol/L, while they stimulated the growth of MTB H37Rv notably at concentration of 10pmol/L in Rpf protein and 100pmol/L in Rpf domain. This stimulation was significantly inhibited after adding 1:600 anti- M.luteus Rpf domain MAb. When the concentration of RpfB domain was 1000pmol/L, stimulation to M.luteus was significant, and When its concentration was 500pmol/L, stimulation to MTB H37Rv was also significant. The stimulation was inhibited after adding 1:1000 anti- RpfB domain MAb.
3. Immunological activity of M.luteus Rpf protein, Rpf domain and RpfB domain
To test immunological properties of the proteins, BALB/c mice were immunized three times at 2-week interval subcutaneously on their backs with Rpf , Rpf domain and RpfB domain proteins respectively, which were transferred to NC membranes beforehand. The titers of specific antibody in BALB/c mice were detected by ELISA. The results suggested average titers of anti-Rpf was 1:12800, that of Rpf domain was 1:4800, and that of RpfB domain was 1:6400.
To evaluate cell-mediated immune response, stimulating index(SI) of the spleen lymphocytes in immunized mice were measured by MTT method, the SI of Rpf , Rpf domain and RpfB domain were significantly higher(which were 2.86±0.12 for Rpf, 2.10±0.09 for Rpf domain, 2.40±0.11 for RpfB domain than that of normal saline controls ( P<0.05 ) , but lower than that of BCG groups(3.50±0.23)(P<0.05).The levels of IFN-γ, IL-10 and IL-12 secretion stimulated by specific antigen were detected by indirect ELISA. IFN-γ, IL-10 and IL-12 concentrations in cultured supernatant of spleen lymphocytes from mice immunized with Rpf protein were 1528±36 ng/L, 485±13 ng/L and 302±14 ng/L respectively. The levels of three cytokines mentioned above stimulated by Rpf domain protein were 1126±36 ng/L, 368±13 g/L and 289±14 ng/L respectively, while thats of RpfB domain protein were 1432±30 ng/L, 503±11 ng/L, and 311±11 ng/L respectively. In group immunized by BCG, the average levels of IFN-γ,IL-10 and IL-12 were 2022±38 ng/L, 578±13 ng/L and 400±10 ng/L respectively; while in normal saline groups, the average levels of IFN-γ,IL-10 and IL-12 were 256±6 ng/L, 76±3 ng/L and 56±4 ng/L. From above results, we found the levels of three cytokines immunized by three proteins were significantly higher than that of normal saline groups(p<0.01), but lower than that of BCG groups. (p<0.05).
In order to test our three proteins’efficacies against MTB H37Rv, BALB/c mice were intravenously infected with 105 CFU MTB H37Rv. four weeks after the final immunization, the numbers of MTB CFU in spleens were determined. Compared with the normal saline groups, Bacteria loads in the three protein groups were dramatic reduction(differences were 1.89 log10, 1.61 log10 and 1.78 log10 respectively,P<0.05). But the protective efficacies of mice immunized with proteins were lower than that of BCG vaccination group(2.83 Log10) (p<0.05).
CONCLUSION:
M.luteus Rpf, Rpf domain and RpfB domain proteins could stimulate the resuscitation and growth of M.luteus dormant and MTB H37Ra dormant. MAb of the two domain could significantly inhibited the effectiveness of growth promotion and specifically identified many kinds of Rpf and Rpf domain. They also could induce high level cell-mediated immune reponse and confer effective protection against TB. So they may be an appropriate candidate for culture medium additives which promote growth of dormant MTB in order to elevate detection rate of subclinical patients. We can establish detection methods on MTB related antigen according to our results. At the same time, they may be new candidate for vaccine to TB control and prophylaxis.
近年来研究发现,在MTB休眠菌的复苏过程中,MTB分泌的5种促进复活因子(Resuscitation promoting factor,Rpf)起了重要作用,分别为Rv0867c(RpfA),Rv1009(RpfB),Rv1884c(RpfC),Rv2389c(RpfD)和Rv2450c(RpfE)。Rpf最早在藤黄微球菌(Micrococcus luteus,M.luteus)中发现。通过同源性分析发现,Rpf存在于多种富含G+C的革兰阳性细菌中,其基因编码的蛋白均具有Rpf样结构域。在研究中发现,Rpf蛋白的结构域与完整Rpf蛋白具有一致的生物学特性。对Rpf家族的研究还发现,Rpf样蛋白不仅与细菌的增殖有关,还可能是宿主免疫系统识别的靶抗原。
在本研究中,我们分别克隆、表达和纯化了藤黄微球菌Rpf蛋白、Rpf结构域蛋白、RpfB结构域蛋白;制备了抗藤黄微球菌Rpf结构域和抗RpfB结构域的单克隆抗体(monoclonal antibody,MAb);研究了藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白的生物学功能和免疫学特性。评价其用于MTB分离培养添加剂、相关抗原检测方法建立及TB新型疫苗研制的可能性。实验目的:利用大肠杆菌表达系统表达并纯化藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白;制备抗藤黄微球菌Rpf结构域、抗RpfB结构域的MAb;进一步研究其生物学功能和免疫学特性。
实验方法和结果:
1.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的克隆、表达与纯化采用PCR方法分别从藤黄微球菌和MTB H37Rv的基因组中分别扩增出相应大小的藤黄微球菌Rpf、Rpf结构域和RpfB结构域目的基因片段,并分别克隆入pUC-19载体中测序,结果与GenBank报道的完全一致。将目的基因分别克隆人pProEX HTb表达载体中,酶切鉴定后,分别在E.coli中由IPTG诱导表达目的蛋白。经SDS-PAGE分析,表达的3种目的蛋白与预期分子量一致;Western-blot分析表明3种融合6×His的目的蛋白均可与抗6×His MAb特异反应。3种目的蛋白均以包涵体的形式表达,用亲和色谱法在变性条件下分别纯化3种目的蛋白。
2.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的生物学功能研究
2.1抗藤黄微球菌Rpf结构域、抗RpfB结构域MAb的制备及鉴定
用藤黄微球菌Rpf结构域蛋白分别免疫BALB/c小鼠,进行细胞融合,获得了3株能稳定分泌抗藤黄微球菌Rpf结构域MAb的杂交瘤细胞系,分别命名为F3D10、G10D5、G6C8,其中F3D10、G10D5为IgG1亚类,G6C8为IgM亚类,其相对亲和力为F3D10>G6C8>G10D5;用RpfB结构域蛋白免疫BALB/c小鼠,进行细胞融合,获得了3株能稳定分泌抗RpfB结构域MAb的杂交瘤细胞系,分别命名为D3A5、B8G11、A9C8,其中D3A5、B8G11为IgG1亚类,A9C8为IgM亚类,其相对亲和力为A9C8>D3A5>B8G11。
分别构建了pcDNA3.1(-)-Rpf结构域及pcDNA3.1(-)-RpfB结构域真核表达载体,转染COS-7细胞,用间接免疫荧光法检测表明藤黄微球菌Rpf结构域蛋白和RpfB结构域蛋白在COS-7细胞中有表达,也间接验证了MAb的特异性。
2.2抗藤黄微球菌Rpf结构域及抗RpfB结构域MAb的交叉实验。分别用藤黄微球菌Rpf、Rpf结构域、RpfB结构域、RpfA(本实验室纯化的MTB RpfA蛋白,质粒为国外Mike Young教授馈赠)及H37Ra作为抗原与制备的两种MAb反应,结果显示:两种抗结构域MAb均可以与以上蛋白和H37Ra菌株发生反应。
2.3藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白促藤黄微球菌及MTB H37Ra休眠菌的复苏和生长作用
取藤黄微球菌和MTB H37Ra的休眠菌适当稀释后,随机分为3组。每组分别加入不同稀释浓度的纯化蛋白及相应的抗结构域MAb,取不同时间点的培养液测OD600值,绘制生长曲线。结果显示:当藤黄微球菌Rpf和Rpf结构域浓度均为100pmol/L时,刺激藤黄微球菌复苏和生长作用明显,当藤黄微球菌Rpf浓度为10pmol/L、Rpf结构域浓度为100pmol/L时,刺激MTB H37Ra复苏和生长作用明显,而且这种刺激作用在加入了1:600的抗藤黄微球菌Rpf结构域MAb后明显被抑制;当RpfB结构域浓度为1000pmol/L时,刺激藤黄微球菌复苏和生长作用明显,当RpfB结构域浓度为500pmol/L时,刺激MTB H37Ra复苏和生长作用明显,而且这种刺激作用在加入了1:1000的抗RpfB结构域MAb后明显被抑制。
3.藤黄微球菌Rpf、Rpf结构域和RpfB结构域的免疫学特性研究
采用皮下包埋的方法,分别将藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白滴到硝酸纤维素膜小块上,免疫小鼠3次,每次间隔2周,同时设BCG免疫组和生理盐水对照组。用ELISA方法检测免疫小鼠血清中的特异性抗体平均滴度。结果显示:藤黄微球菌Rpf蛋白免疫组最高抗体效价为1:12800,藤黄微球菌Rpf结构域蛋白免疫组最高抗体效价为1:4800,RpfB结构域蛋白免疫组最高抗体效价为1:6400。
为了检测蛋白免疫小鼠引起的细胞免疫应答,最后一次免疫完成两周后,分离各免疫组小鼠脾淋巴细胞,在体外经PPD刺激后,MTT法检测淋巴细胞增殖反应,藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白免疫小鼠后的刺激指数分别为:2.86±0.12,2.10±0.09,2.40±0.11,明显高于生理盐水对照组(0.90±0.21)(P<0.01),但不及BCG免疫组(3.50±0.23)(P<0.05)。藤黄微球菌Rpf蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1528±36ng/L,485±13ng/L和302±14ng/L;藤黄微球菌Rpf结构域蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1126±36ng/L,368±13ng/L和289±14ng/L;RpfB结构域蛋白诱导产生的IFN-γ,IL-10和IL-12平均水平分别为1432±30ng/L,503±11ng/L和311±11ng/L;BCG免疫组诱导产生的IFN-γ,IL-10和IL-12平均水平分别为2022±38ng/L,578±13ng/L和400±10ng/L;生理盐水对照组IFN-γ,IL-10和IL-12水平分别为256±6ng/L,76±3ng/L和56±4ng/L。从结果可以看出,3种蛋白免疫小鼠后诱导产生的细胞因子水平明显高于生理盐水对照组(p<0.01),但不及BCG免疫组(p<0.05)。
免疫完成后第四周,用105CFU MTB H37Rv毒株经尾静脉攻击上述各免疫组小鼠,计数脾脏细菌负荷数。与生理盐水对照组相比,藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白免疫组小鼠对H37Rv毒株攻击后MTB在脾脏中的增殖均有显著抑制作用(差值分别为1.89 log10、1.61 log10和1.78 log10)(p<0.05),但不如BCG免疫组(差值为2.83 log10)(p<0.05)。
结论:藤黄微球菌Rpf、Rpf结构域和RpfB结构域蛋白均具有促进藤黄微球菌和MTB休眠菌复苏和生长的作用,有望用于临床标本分离培养的添加剂,促进MTB休眠菌的复苏和生长,从而提高隐性感染者的检出率;抗两种结构域的MAb不仅可以明显抑制3种蛋白的促复苏和生长作用,而且可以特异性的识别多种Rpf蛋白及其结构域,据此,有可能建立MTB相关抗原的检测方法;3种蛋白免疫动物后诱导产生的特异性免疫应答,对MTB毒株的攻击具有一定的保护力,它们有可能用于TB新型疫苗的研制。
Tuberculosis (TB) is a chronic respiratory infectious disease caused by the pathogen Mycobacterium tuberculosis (MTB). It has been one of the most important contributory and mortiferous factors in the world. It is estimated by WHO that one-third of the world population are infected with MTB. In China, the number of TB patients was the second in the world, approximately 400 million people infected. 10% of these people will develop to activity TB, and the most of infected MTB exist in condition of dormant infection. This dormant MTB has strong drug resistance, it can exist in vivo for a long time, and it’s difficult to isolate and cultivate. The current vaccine against MTB, M. bovis Bacillus Calmette-Guérin(BCG)has many problems such as ineffective to subclinical infection,short period of protect and low immune response. Current preventive measures and diagnosis methods have no effect on MTB dormant. So it is great significant for studying new diagnosis reagents, therapy methods and vaccines to prevent TB, especially for dormant infection.
Recent studies showed that the resuscitation promoting factor(Rpf) which secreted by MTB played a important role in promoting the resuscitation and growth of dormant mycobacterium, Rv0867c(RpfA),Rv1009(RpfB),Rv1884c(RpfC),Rv2389c(RpfD)and Rv2450c(RpfE). Rpf was first discovered in Micrococcus luteus(M.luteus). Homology analysis suggests that Rpf-like protein widely distribute among high G+C Gram-positive bacteria. It has been found the domain of Rpf has the same biological characteristics as Rpf-like protein. It also has been demonstrated that Rpf-like protein can not only stimulate the resuscitation of stationary-phase mycobacterial, including M. bovis BCG and MTB, but also a target antigen of immune system of host. In this study, we cloned, expressed and purified M.luteus Rpf protein, M.luteus Rpf domain protein and RpfB domain protein, generated MAb of M.luteus Rpf domain and RpfB domain. Furthermore, we studied the biological function and immunological characteristics of them, in order to evaluate the possibility of using them to rapidly isolate and cultivate MTB, detect related antigen, and become candidate vaccines.
AIM: To express and purify M.luteus Rpf protein, Rpf domain and RpfB domain.To generate MAb of M.luteus Rpf domain and RpfB domain .To study the biological and immunological properties of M.luteus Rpf, Rpf domain and RpfB domain.
METHODS AND RESULTS:
1. Cloning, expression and purification of M.luteus Rpf protein, Rpf domain and RpfB domain
The genes of M.luteus Rpf, Rpf domain and RpfB domain were amplified respectively from genome of M.luteus and MTB H37Rv strain by using polymerase chain reaction(PCR). Inserted the PCR product into pUC-19 vector accordingly and sequenced. The DNA sequence of M.luteus Rpf, Rpf domain and RpfB domain were identical with that published by GenBank. After sequencing was confirmed, Subcloned the three right sequenced genes into pPRO-EXHT prokaryotic expression vector . The recombinant clones were screened restriction enzyme analysis and transformed into E.coli DH5αstrain and induced with IPTG. The analysis of SDS-PAGE showed that there were specific protein expressions at the corresponding positions as we anticipated. The three proteins were further identified by Western-blot using anti-6×His MAb.Purified theproteins by Ni-NTA purification system under denaturing conditions.
2. Biological Activity Of M.luteus Rpf protein, Rpf domain and RpfB domain
2.1 Construction and identification of MAbs to M.luteus Rpf domain and RpfB domain
We obtained 3 hybridoma cell strains which could stablely secrete antibodies adainst M.luteus, named F3D10,G10D5 and G6C8 from BALB/c mice immunized with. The subclass of F3D10 and G10D5 is IgG1,while the subclass of G6C8 is IgM. The relative affinity of the MAbs are different and the sequence is A9C8>D3A5>B8G11.We also obtained 3 hybridoma cell strains which could stablely secrete antibodies adainst RpfB domain ,named D3A5,B8G11 and A9C8. The subclass of D3A5 and B8G11 is IgG1,while the subclass of A9C8 is IgM. The relative affinity sequence of the MAbs is A9C8>D3A5>B8G11.
In order to identify the specificity of the MAb, we constructed eukaryotic expression vector pcDNA3.1(-)-Rpf domain and pcDNA3.1 (-)-RpfB domain, and expressed in COS-7 cells. The specificity of the MAb was confirmed with indirect immunofluorescence.
2.2 Cross test of anti-M.luteus Rpf domain and anti-RpfB domain.
Cross test of the two constructed MAbs were detected by ELISA, using Rpf, Rpf domain, RpfB domain, and other Rpf proteins of MTB as antigen to invest culture plate respectively and the two constructed MAbs to be the first antibody. The results showed both MAbs have reaction with all above proteins.
2.3 The promotive action of resuscitation and growth of M.luteus Rpf, Rpf domain and RpfB domain on M.luteus and MTB
H37Ra and M.luteus dormant strains were at a suitable dilution using culture medium, and then divided into 3 groups randomly. Different concentration proteins were added to each group respectively. Taken 200μl from each group at different time to detected the OD600. The results showed that Rpf protein and Rpf domain could significantly stimulate the growth of M.luteus at concentration of 100pmol/L, while they stimulated the growth of MTB H37Rv notably at concentration of 10pmol/L in Rpf protein and 100pmol/L in Rpf domain. This stimulation was significantly inhibited after adding 1:600 anti- M.luteus Rpf domain MAb. When the concentration of RpfB domain was 1000pmol/L, stimulation to M.luteus was significant, and When its concentration was 500pmol/L, stimulation to MTB H37Rv was also significant. The stimulation was inhibited after adding 1:1000 anti- RpfB domain MAb.
3. Immunological activity of M.luteus Rpf protein, Rpf domain and RpfB domain
To test immunological properties of the proteins, BALB/c mice were immunized three times at 2-week interval subcutaneously on their backs with Rpf , Rpf domain and RpfB domain proteins respectively, which were transferred to NC membranes beforehand. The titers of specific antibody in BALB/c mice were detected by ELISA. The results suggested average titers of anti-Rpf was 1:12800, that of Rpf domain was 1:4800, and that of RpfB domain was 1:6400.
To evaluate cell-mediated immune response, stimulating index(SI) of the spleen lymphocytes in immunized mice were measured by MTT method, the SI of Rpf , Rpf domain and RpfB domain were significantly higher(which were 2.86±0.12 for Rpf, 2.10±0.09 for Rpf domain, 2.40±0.11 for RpfB domain than that of normal saline controls ( P<0.05 ) , but lower than that of BCG groups(3.50±0.23)(P<0.05).The levels of IFN-γ, IL-10 and IL-12 secretion stimulated by specific antigen were detected by indirect ELISA. IFN-γ, IL-10 and IL-12 concentrations in cultured supernatant of spleen lymphocytes from mice immunized with Rpf protein were 1528±36 ng/L, 485±13 ng/L and 302±14 ng/L respectively. The levels of three cytokines mentioned above stimulated by Rpf domain protein were 1126±36 ng/L, 368±13 g/L and 289±14 ng/L respectively, while thats of RpfB domain protein were 1432±30 ng/L, 503±11 ng/L, and 311±11 ng/L respectively. In group immunized by BCG, the average levels of IFN-γ,IL-10 and IL-12 were 2022±38 ng/L, 578±13 ng/L and 400±10 ng/L respectively; while in normal saline groups, the average levels of IFN-γ,IL-10 and IL-12 were 256±6 ng/L, 76±3 ng/L and 56±4 ng/L. From above results, we found the levels of three cytokines immunized by three proteins were significantly higher than that of normal saline groups(p<0.01), but lower than that of BCG groups. (p<0.05).
In order to test our three proteins’efficacies against MTB H37Rv, BALB/c mice were intravenously infected with 105 CFU MTB H37Rv. four weeks after the final immunization, the numbers of MTB CFU in spleens were determined. Compared with the normal saline groups, Bacteria loads in the three protein groups were dramatic reduction(differences were 1.89 log10, 1.61 log10 and 1.78 log10 respectively,P<0.05). But the protective efficacies of mice immunized with proteins were lower than that of BCG vaccination group(2.83 Log10) (p<0.05).
CONCLUSION:
M.luteus Rpf, Rpf domain and RpfB domain proteins could stimulate the resuscitation and growth of M.luteus dormant and MTB H37Ra dormant. MAb of the two domain could significantly inhibited the effectiveness of growth promotion and specifically identified many kinds of Rpf and Rpf domain. They also could induce high level cell-mediated immune reponse and confer effective protection against TB. So they may be an appropriate candidate for culture medium additives which promote growth of dormant MTB in order to elevate detection rate of subclinical patients. We can establish detection methods on MTB related antigen according to our results. At the same time, they may be new candidate for vaccine to TB control and prophylaxis.
引文
1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione RC, Consensus statement. Global burden of tuberculosis–estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project, JAMA (J Am Med Assoc).1999;(282): 677–686.
2. Gangadharam P.R, Mycobacterial dormancy. Tuber Lung Dis. 1995;(76):477–479.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic, Arch. Intern. Med. 2003; (163):1009-1021.
4. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermun SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection, N. Engl. J. Med. 1989; (320): 545–550.
5. Fine PE, Variation in protection by BCG: implication of and for Heterologous immunity. Lancet. 1995; (346):1339-1345.
6. Mukamolova GV, Kaprelyants AS, Young DI, Young, M., and Kell D.B.. A bacterial cytokine [J]. Proc Natl Acad Sci USA,1998,95(15):8916–8921.
7. Zhu W, PlikaytisBB ,Shinnick TM. Resuscitation factors from mycobacteria: homologs of Micrococcus luteus proteins.Tuberculosis (Edinb), Jan 2003;83(4):261-269.
8. Mukamolova GV,Murzin AG,etal.Muralytic activity of micococcus luteus Rpf and relationship to physiological activity in promoting bacterial growth and resuscitation. Mol.Microbiol,2006,59(1):84-89
9. World Health Organization Global Tuberculosis Control-Surveillance, Planning, Financing [R]. WHO Report, Geneva, Switzerland, 2006.
10. 全国结核流行病学抽样调查技术指导组. 第四次全国结核流行病学抽样调查报告[J].中华结核和呼吸杂志,2002,25(1):3-7。
11. 郝阳. 我国结核病防治概况与今后工作设想[J]. 中华结核和呼吸杂志,2004,27(7):433-435.
12. FlynnJL,ChanJ.Tuberculosis:Latency and reactivation [J].Infect Immun,2001, 69(7): 4195-4201
13. UlrichsT,Kaufmann SH.Mycobacterial persistence and immunity[J]. FronTBiosci,2002, 7:458-469.
14. Boom WH, Chervenal KA, Mincek MA, Ellneret JJ. Role of the mononuclear phagocyte as an antigen-presenting cell for human cells activated by live mycobacterium tuberculosis. Infect Immun,1992,60(9):3480-3488.
15. Steffen Stenger, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin in Microbiol,1999, 2(1):89-93.
16. Flynn JL, Ernst JD. Immune responses in tuberculosis. Curr Opin Immunol, 2000, 12(4): 432-436.
17. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JFAP. CD4+T Cell Help Impairs CD8+T Cell Deletion Induced by Cross- presentation of Self-Antigens and Favors Autoimmunity. J Exp Med,1997,186(12):2057-2062.
18. Lazarevic V, Flynn J. CD8+T Cells in Tuberculosis. Am J Respir Crit Care Med, 2002, 166(8):1116-1121.
19. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest, 1991,87(2):729-733.
20. Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer.J Immunol,1995,154(3):998-1006.
21. Johnson BJ, Ress SR, Willcox P, Pati BP, Lorgat F, Stead P, Saha R, Lukey P,Laochumroonvorapong P, Corral L. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther, 1995,1(3):185-196.
22. Shingo H, Naoyuki N, Takeshi K, Kibata M. Preliminary evaluation of soluble IL-2 receptor and type III procollagen N-terminal aminopeptide in pleural fluid for differentiating tuberculous, carcinomatous and parapneumonic pleural effusions. Respirology, 2002,7(4):311-315.
23. 何炬斌. 白细胞介素-2 在结核病治疗中的应用.上海免疫学杂志, 1994,14(4):245-246.
24. Gazzinell RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early synthesis and resistance during acute infection with Toxoplasma gondii.J Immunol, 1994, 153(6):2533-2543.
25. Rhoades ER, Goopper AM, Omne IM. Chemokine response in mice infected with Mycobacterium tuberculosis.Infect Immun,1995,63(10):3871-3877.
26. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin-12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med,1997,186(1):39-45.
27. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol,1995, 155(5): 2515-2524.
28. Das G, Sheridan S, Janeway CA. The Source of Early IFN-γ That Plays a Role in Th1 Priming.J. Immunol, 2001,167(4): 2004-2010.
29. Lyadova I, Yeremeev V, Majorov K, Nikonenko B, Khaidukov S, Kondratieva T, Kobets N, Apt A. An ex vivo study of T Lymphocytes recovered from the lungs of I/St mice infected with and susceptible to Mycobacterium tuberculosis.Infec.Immun, 1998,66(10): 4981- 4988.
30. Orme I, Miller E, Roberts A, Furney SK, Griffin JP, Dobos KM, Chi D, Rivoire B,Brennan PJ. T Lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection.J Immunol,1992,148(1):189-196.
31. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in IFN-γ gene-disrupted mice.J Exp Med, 178(6): 2243-2248.
32. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for Interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med.178(6): 2249-2254.
33. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AVS. Human cytolytic and interferon gamma- secreting CD8 T lymphocytes specific for Mycobacterium tuberculosis. PNAS, 1998, 95(1):270-275.
34. Ottenhoff TH, Kumararatne D, Casanova JL. Noval human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria.Immunol Today, 1998,19(11):491-494.
35. Ladel CH, Szalay G, Reidel D, Kaufmann SH. Interleukin-12 secretion by Mycobacterium tuberculosis infected macrophages.Infect Immun,1997,65(5):1936-1938.
36. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis.J Immunol,1997,159 (2):635-643.
37. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor is required in the protective immune response against M.tuberculosis in mice.Immunity,1995,2(6):561-572.
38. Bean AGD, Roach DR, Briscoe H, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.J Immunol,1999,162(6): 3504-3511.
39. Moreira AL, Tsenova L, Wang J, Laochumroonvorapong P, Freeman S, Freedman VH, Kaplan G. Effect of cytokine modulation by thalidomide on the gramomatous response inmurine tuberculosis.Tubercle Lung Disease, 1997,78(1):47-55.
40. Hodge DJ, Marino MW, Horton MR, Jungbluth A, Burdick MD, Strieter RM, Noble PW, Hunter CA, Puré E. Inhibition of interferon induced interleukin 12 production:a potential mechanism for the anti-inflammatory activities of tumor necrosis factor.PNAS,1998, 95(23):13806-13811.
41. Fenhalls G, Wong A, Bezuidenhout J, l van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon,interleukin-4,and tumor necrosis factor alpha mRNA in human lung tuberculous granuloma.Infect Immun, 2000,68(5):2827-2836.
42. Gong J, Zhang M, Modlin R, Linsley PS, Iyer D, Lin Y, Barnes PF. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA4 expression. Infect Immun, 1996,64(3):913-918.
43. Rojas M, Olivier M, Gros P, Barrera LF, García LF. TNFα and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages.J. Immunol, 1999,162(10):6122-6131.
44. Ladel R, Miyajima A, Mee PJ, Tybulewicz VL, Murray R. Lethal tuberculosis in interleukin-6-deficient mutant mice.Blood,1996,88(7):2458-2464.
45. Reed JA, Ikegami M, Robb L, Begley CG, Ross G, Whitsett JA. Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytes.AmJ Physiol Lung Cell Mol Physiol,2000,278(6):1164-1171.
46. Connell ND. Mycobacterium: isolation, maintenance, transformation, and mutant selection. Methods Cell Biol. 1994; (45):107–125.
47. Wayne,L.G,Sohaskey,C.D.Non-replicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol ,2001;55,139-163.
48. 戚中田.医学微生物学.北京:科学出版社, 2003.199-209.
49. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R, O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R,O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D. Lipoprotein access to MHC Class I presentation during infection of routine macrophages with live Mycobacteria. J Immun, 2001,166(1):447-457.
50. Couture M, Yeh SR, Wittenberg BA, Wittenberg JB, Ouellet Y, Rousseau DL, Guertin M. A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. PNAS, 1999, 96(20):11223-11228.
51. Weber I, Fritz C, Ruttkowski S, Kreft A, Bange FC. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol, 2000,35(5):1017-1025.
52. 顾晓玲, 张红梅, 王洪海.结核分枝杆菌持续感染期分子机制的研究进展.中华结核和呼吸杂志,2005,28(1):47-49.
53. 江山.结核分枝杆菌潜伏性感染发生机制的研究进展.国外医学:微生物学分册,2003, 26(1):31-33.
54. Gatfield J, Pieters J. Essential role for cholesterol in entry of Mycobacteria into macrophages.Science,2000, 288(5471):1647-1650.
55. Pasula R,Wright JR, Kachel DL, Martin WJ. Surfactant protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis. J Clin Invest,1999,103(4):483-490.
56. Mahenthiralingam E, Marklund BI, Brooks LA, Smith DA, Bancroft GJ, Stokes RW. Site-Directed Mutagenesis of the 19-Kilodalton Lipoprotein Antigen Reveals No Essential Role for the Protein in the Growth and Virulence of Mycobacterium intracellulare. Infect Immun,1998,66(8):3626-3634.
57. Via LE, Deretic D, Ulmer RJ, Hibler NS, Huber LA, Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J Biol Chem,1997,272(20):13326-13331.
58. Pieters J. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect,2001,3(3):249-255.
59. Anand PK, Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol Lett,2005, 250(1):137-144.
60. Voss JJD, Rutter K, Schroeder BG, Barry CE. Iron Acquisition and Metabolism by Mycobacteria. J Bacteriol, 1999,181(15):4443-4451.
61. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol, 2001, 41(1):179-187.
62. Braunstein M, Espinosa BJ, Chan J, Belisle JT, Jacobs WR Jr. Braunstein M, Espinosa BJ, Chan J, Belisle JT, Jacobs Jr WR. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol Microbiol, 2003, 48(2):453-464.
63. Chan J, Kaufmann S. Immune mechanisms of protection in tuberculosis pathogenesis, protection and control. Bloom, B.R. Ed. American Society of Microbiology. 1994. Washington, D.C.9389-415.
64. Behr MA,Wilon MA,Gill WP,et al.Comparative genomics of BCG vaccines By whole genome DNA microarry.Science,1999;284:1520-1523.
65. Lewis KN, Liao R, Guinn KM,etal Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation.J Infect Dis. 2003 ;187(1):117-123.
66. Brandt L, Cunha JF, Olsen AW et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis [J]. Infect Immun. 2002, 70(5): 672–678.
67. Hubbard RD, Flory CM, FM Collins. Immunization of mice with mycobacterial culture filtrate proteins.Clin Exp Immunol, 1992,7(1):94-98.
68. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in miceJ. Immunol, 1995,154(7):3359-3372.
69. Sonnenberg MG, Belisle JT. Definition of Mycobacterium tuberculosis culture filtrateproteins by two-dimensional polyacrylamide gel electrophoresis, N- terminal amino acid sequencing, and electrospray mass spectr- ometry.Infect Immun,1997,65(1):4515-4524.
70. Daudi cells analyzed by TCR gene transfer.J Immunol,1995;154(3):998-1006.
71. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in IFN-γ gene-disrupted mice.J Exp Med, 178(6):2243-2248.
72. Anderson P, Askgaard D, Gottschau A, Bennedsen J, Nagai S, Heron I. Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand J Immunol,1992;36(6):823-831.
73. Stenger S. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science,1998;282(5386):121-125.
74. Lowrie DB, Silva CL. Enhancement of immunocompetence in tuberculosis by DNA vaccination.Vaccine, 2000(18):1712-1716.
75. 范雄林, 李元, 徐志凯.结核分枝杆菌基因疫苗研究进展.细胞与分子免疫学杂志, 2001,17(4):121-123.
76. 师长宏. 融合表达 Ag85B-ESAT6 的增强型结核分枝杆菌疫苗研究. 第四军医大学博士论文. 2004 年.
77. Morris S, Kelley C, Howard A, et al. The immunogenicity of single and combination DNA vaccines against tuberculosis [J]. Vaccine, 2002, 18(1):2155-2163.
78. Kamath AT, Feng CG, Macdonald M, et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis [J].Infect Immun. 1999, 67(4):1702-1707.
79. Skinner MA, Ramsay AJ, Buchan GS, et al. A DNA prime live vaccine boost strategy in mice can augment IFN-gamma responsesto mycobacterial antigens but does not increase the p rotective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis [J]. Immunology. 2003,108(4):548-555
80. Orme IM. Current progress in tuberculosis vaccine development [J].Vaccine,2005, 23(4):2105-2108.
81. Dai W, Huang H, Yuan Y,etal .Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.Int J Med Microbiol,2003 ;292 (7-8) :441-451.
82. Horwitz MA, Harth G, Dillon BJ, et al. Recombinant bacillus Calmette-Guerin (BCG) vaccined expressing the major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model [J]. Proc Natl Acad Sci USA. 2000,97(25):13853-13858.
83. Gedde MM,Higgins DE,Tilney LG,et al.Role of listeriolysin in cell-to-cell spread of Listeria monocytogenes.Infect Immun, 2000,68(2):999-1003.
84. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette Guerin strains secreting listeriolysin of Listeria monocytogenes. PNAS,1998,95(9):5299-5304.
85. Dhar N, Rao V, Tyagi AK,etal.Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system..Immunol Lett, 2003;88(3):175-184.
86. Ghedrghiu M,Lagranderie MRR,Gicquel BME,et al.Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen.Infection Immunity,1994;62(10):4287-4295.
87. 胡佳杰, 文学明, 肖爱清等. 重组 M.S-Sj26GST 疫苗有关毒性实验研究[J]. 华南预防医学, 2002; 28(5):44-45.
88. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 11: 455–459.
89. 王永其. 对 MTB 涂片染色的评价. 临床肺科杂志. 2000;5:123-124.
90. 陆宇,朱莉贞,段连山. 结核分枝杆菌活菌检测方法及应用[J]. 中华结核和呼吸杂志. 2004;(6):423-425.
91. Gingeras TR. RNA reference materials for gene expression studies. Difficult first steps. Clin Chem. 2004; 50 (8): 289-1290.
92. Gilpin C, Abdelaal MA, Osoba AO. Rapid diagnosis of Mycobacterium tuberculosis by Amplicor PCR and LCR in a Clinical Laboratory. Ann Saudi Med. 1997 Sep; 17(5): 572-574.
93. Stocher M, Leb V, Berg I. A convenient approach to the generation of multiple internal control DNA for a panel of real-time PCR assays [J]. Virol Methods, 2003;108 (1):1-8.
94. Troesch A, Nguyen H, Miyada CG, Desvarenne S, Gingeras TR, Kaplan PM, Cros P, Mabilat C. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol. 1999; 37 (1): 49-55.
95. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A. 1999;96 (22): 12833-12838.
96. Chan ED, Heifets I, Iseman MD.Immunogic diagnosis of tuberculosis: a Review [J]. Tubercle and Lung Disease. 2000; 80 (3):131-140.
97. 孔忠顺,管波清,古淑香,等. 血清抗脂阿拉伯甘露糖及 38KD 抗体检测对涂阴肺结核及肺外结核诊断价值[J]. 中国防痨杂志. 2002;24(3):140–142.
98. Menzies R, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis.1992; 145:621–625.
99. 何俊瑛,黄庆生. 脑脊液单核细胞内结核抗原检测对结脑早期诊断的意义[J]. 脑与神经疾病杂志,2005,13(3):201-206.
100. Gangadharam PR. Mycobacterial dormancy. Tuber Lung Dis. 1995; 76 (6): 477-479.
101. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64 (6):2062-2069.
102. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J ClinMicrobiol Infect Dis. 1994;13 (11):908-914.
103. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol.1998; 180 (4):801-808.
104. Hu YM, Butcher PD, Sole K, Mitchison DA, Coates AR. Protein synthesis isshutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett. 1998;158 (1):139-145.
105. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J Bacteriol.1999;(181):2252–2256.
106. Shleeva M, Mukamolova GV, Young M, et al. Formation of 'non-culturable' cells of Mycobacterium smegmatis in stationary phase in response to growth under suboptimal conditions and their Rpf-mediated resuscitation[J]. Microbiology. 2004;150(6): 1687- 97.
107. DeMaio J, Zhang Y, Ko C, Young DB, Bishai WR. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1996;93 (7): 2790-2794.
108. Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK. AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors. 1999; 10 (2-3): 211-217.
109. Biketov S Biketov S, Mukamolova GV, Potapov V.Culturability of Mycobacterium tuberculosis cells isolated from murine macrophages:a bacterial growth factor promotes recovery. FEMS Immunol Med Microbiol, 2000,29(4):223-240.
110. Cohen-Gonsaud M , Keep N H , Davies A P , Ward J., Henderson B., Voloshin S A ; Kaprelyants A S. Voloshin S.A. , Kaprelyants A.S...Resuscitation-promoting factors possess a lysozyme-like domain [J ].Trends Biochem Sci,2004,29(1):7-10.
111. The structure of a resuscitation-promoting factor domain from Mycobacterium tuberculosis shows homology to lysozymes [J ].Nat Struct Mol Biol,2005,12(3):270-273.
112. Mukamolova G V , Murzin A G, Salina E G, Demina,G.R.,Kell,D.B.,Kaprelyants,A.S. Muralytic activity of Micrococcus luteus Rpf and its relationship to physiological activity in promoting bacterial growth and resuscitation [ J ] .Mol Microbiol , 2006,59(1):84-89.
113. Mukamolova GV,Turapov OA,Young DI,Kaprelyants AS, Kell DB and Young. ML A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol 2002,46(3):623–635.
114. Tufariello JM.,Jacobs WR.Individual Mycobacterium tuberculosis resuscitation promoting factor homologues are dispensable for growth in vitro and in vivo. Infect. Immun. 2004;72:515–526
115. Zhu, G., H. Xiao, V. P. Mohan, K. Tanaka, S. Tyagi, F. Tsen, P. Salgame, and J. Chan.. Gene expression in the tuberculous granuloma: analysis by laser capture microdissection and real-time PCR. Cell. Microbiol. 2003;5:445–453.
116. Shleeva M, Mukamolova GV, Young M,et al.Formation of 'non-culturable' cells of Mycobacterium smegmatis in stationary phase in response to growth under suboptimal conditions and their Rpf-mediated resuscitation. Microbiology.2004;150(Pt 6):1687-97.
117. Vladimir V. Yeremeev, Tatiana K. Kondratieva, Elvira I. Rubakova, et al. Proteins of the Rpf Family: Immune Cell Reactivity and Vaccination Efficacy against Tuberculosis in Mice [J]. Infect Immun. 2003 August;71(8): 4789–4794.
118. Downing,K.J.,Mischenko,V.V.,Shleeva,M.O.,Young,D.I.,Young,M.,Kaprelyants,A.S.,Apt,A.S.,and Mizrahi,V. Mutants of Mycobacterium tuberculosis Lacking Three of the Five rpf-Like Genes Are Defective for Growth In Vivo and for Resuscitation In Vitro Infect Immun. 2005,73(5) 3038–3043
119. Downing KJ, Betts JC, Young DI, McAdam RA, Kelly F, Young M, Mizrahi V. Global expression profiling of strains harbouring null mutations reveals that the five rpf-like genes of Mycobacterium tuberculosis show functional redundancy. Tuberculosis (Edinb). 2004; 84 (3-4): 167-179.
120. Telkov MV, Demina GR, Voloshin SA, Salina EG, Dudik TV, Stekhanova TN, Mukamolova GV, Kazaryan KA, Goncharenko AV, Young M, Kaprelyants AS. Proteins of the Rpf (resuscitation promoting factor) family are peptidoglycan hydrolases. Biochemistry (Mosc). 2006;71 (4): 414-422.
121. 薛莹.结核分枝杆菌 Rpf 样蛋白生物学及免疫学活性的研究. 第四军医大学博士论文. 2005 年.
122. Fischer B, Sumner I.Isolation. Renaturation and formation of disulfide bonds of eukaryotic proteins expressed in E.coli as inclusion bodies [J]. Biotech Bioeng.1993,41(1):63-66.
123. Fang M, Huang HL.Advances in in vitro refolding of inclusion body proteins [J]. Sheng Wu Gong Cheng Xue Bao.2001,17(6):608-612.
124. 崇波.鼠源性 IgM 类单克隆抗俸的纯化方法. 单克隆抗体通讯 1992, 8(2): 77-79
125. 刘庆良,邵美琪.小鼠IgG类单克隆抗体 3 种纯化方法的比较.单克隆抗体通讯 1992, 8(3):54-56
126. Sgaya S, Fujita K, Kikuchi A, Ueda H, Takakuwa K, Kodama S, Tanaka K. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther, 1996, 7(2): 223-230
127. 高辉,柏银兰,王丽梅等. 结核分枝杆菌 RpfA 蛋白的表达纯化与鉴定. 第四军医大学学报,2006;27(18):1633-1636.
128. Zhu XJ, Venkataprased N, Thangaraj HS, et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis[J]. J Immunol, 1997;158: 5921-5926.
129. Zhang M ,Lin Y, Iyer DV, et al. T cell cytokine responses in human infection with Mycobacterium tuberculosis[J]. Infect Immun, 1995,63: 3231-3234.
130. Rojas M,Olivier M,Gros P,et al. TNFα and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages[J].J.Immunol,1999, 162:6122-6131.
2. Gangadharam P.R, Mycobacterial dormancy. Tuber Lung Dis. 1995;(76):477–479.
3. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C, The growing burden of tuberculosis: global trends and interactions with the HIV epidemic, Arch. Intern. Med. 2003; (163):1009-1021.
4. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermun SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection, N. Engl. J. Med. 1989; (320): 545–550.
5. Fine PE, Variation in protection by BCG: implication of and for Heterologous immunity. Lancet. 1995; (346):1339-1345.
6. Mukamolova GV, Kaprelyants AS, Young DI, Young, M., and Kell D.B.. A bacterial cytokine [J]. Proc Natl Acad Sci USA,1998,95(15):8916–8921.
7. Zhu W, PlikaytisBB ,Shinnick TM. Resuscitation factors from mycobacteria: homologs of Micrococcus luteus proteins.Tuberculosis (Edinb), Jan 2003;83(4):261-269.
8. Mukamolova GV,Murzin AG,etal.Muralytic activity of micococcus luteus Rpf and relationship to physiological activity in promoting bacterial growth and resuscitation. Mol.Microbiol,2006,59(1):84-89
9. World Health Organization Global Tuberculosis Control-Surveillance, Planning, Financing [R]. WHO Report, Geneva, Switzerland, 2006.
10. 全国结核流行病学抽样调查技术指导组. 第四次全国结核流行病学抽样调查报告[J].中华结核和呼吸杂志,2002,25(1):3-7。
11. 郝阳. 我国结核病防治概况与今后工作设想[J]. 中华结核和呼吸杂志,2004,27(7):433-435.
12. FlynnJL,ChanJ.Tuberculosis:Latency and reactivation [J].Infect Immun,2001, 69(7): 4195-4201
13. UlrichsT,Kaufmann SH.Mycobacterial persistence and immunity[J]. FronTBiosci,2002, 7:458-469.
14. Boom WH, Chervenal KA, Mincek MA, Ellneret JJ. Role of the mononuclear phagocyte as an antigen-presenting cell for human cells activated by live mycobacterium tuberculosis. Infect Immun,1992,60(9):3480-3488.
15. Steffen Stenger, Modlin RL. T cell mediated immunity to Mycobacterium tuberculosis. Curr Opin in Microbiol,1999, 2(1):89-93.
16. Flynn JL, Ernst JD. Immune responses in tuberculosis. Curr Opin Immunol, 2000, 12(4): 432-436.
17. Kurts C, Carbone FR, Barnden M, Blanas E, Allison J, Heath WR, Miller JFAP. CD4+T Cell Help Impairs CD8+T Cell Deletion Induced by Cross- presentation of Self-Antigens and Favors Autoimmunity. J Exp Med,1997,186(12):2057-2062.
18. Lazarevic V, Flynn J. CD8+T Cells in Tuberculosis. Am J Respir Crit Care Med, 2002, 166(8):1116-1121.
19. Havlir DV, Ellner JJ, Chervenak KA, Boom WH. Selective expansion of human gamma delta T cells by monocytes infected with live Mycobacterium tuberculosis. J Clin Invest, 1991,87(2):729-733.
20. Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer.J Immunol,1995,154(3):998-1006.
21. Johnson BJ, Ress SR, Willcox P, Pati BP, Lorgat F, Stead P, Saha R, Lukey P,Laochumroonvorapong P, Corral L. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol Ther, 1995,1(3):185-196.
22. Shingo H, Naoyuki N, Takeshi K, Kibata M. Preliminary evaluation of soluble IL-2 receptor and type III procollagen N-terminal aminopeptide in pleural fluid for differentiating tuberculous, carcinomatous and parapneumonic pleural effusions. Respirology, 2002,7(4):311-315.
23. 何炬斌. 白细胞介素-2 在结核病治疗中的应用.上海免疫学杂志, 1994,14(4):245-246.
24. Gazzinell RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, Caspar P, Trinchieri G, Sher A. Parasite-induced IL-12 stimulates early synthesis and resistance during acute infection with Toxoplasma gondii.J Immunol, 1994, 153(6):2533-2543.
25. Rhoades ER, Goopper AM, Omne IM. Chemokine response in mice infected with Mycobacterium tuberculosis.Infect Immun,1995,63(10):3871-3877.
26. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin-12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J Exp Med,1997,186(1):39-45.
27. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol,1995, 155(5): 2515-2524.
28. Das G, Sheridan S, Janeway CA. The Source of Early IFN-γ That Plays a Role in Th1 Priming.J. Immunol, 2001,167(4): 2004-2010.
29. Lyadova I, Yeremeev V, Majorov K, Nikonenko B, Khaidukov S, Kondratieva T, Kobets N, Apt A. An ex vivo study of T Lymphocytes recovered from the lungs of I/St mice infected with and susceptible to Mycobacterium tuberculosis.Infec.Immun, 1998,66(10): 4981- 4988.
30. Orme I, Miller E, Roberts A, Furney SK, Griffin JP, Dobos KM, Chi D, Rivoire B,Brennan PJ. T Lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection.J Immunol,1992,148(1):189-196.
31. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in IFN-γ gene-disrupted mice.J Exp Med, 178(6): 2243-2248.
32. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for Interferon-γ in resistance to Mycobacterium tuberculosis infection. J Exp Med.178(6): 2249-2254.
33. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, Dockrell H, Pasvol G, Hill AVS. Human cytolytic and interferon gamma- secreting CD8 T lymphocytes specific for Mycobacterium tuberculosis. PNAS, 1998, 95(1):270-275.
34. Ottenhoff TH, Kumararatne D, Casanova JL. Noval human immunodeficiencies reveal the essential role of type-1 cytokines in immunity to intracellular bacteria.Immunol Today, 1998,19(11):491-494.
35. Ladel CH, Szalay G, Reidel D, Kaufmann SH. Interleukin-12 secretion by Mycobacterium tuberculosis infected macrophages.Infect Immun,1997,65(5):1936-1938.
36. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis.J Immunol,1997,159 (2):635-643.
37. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor is required in the protective immune response against M.tuberculosis in mice.Immunity,1995,2(6):561-572.
38. Bean AGD, Roach DR, Briscoe H, Briscoe H, France MP, Korner H, Sedgwick JD, Britton WJ. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.J Immunol,1999,162(6): 3504-3511.
39. Moreira AL, Tsenova L, Wang J, Laochumroonvorapong P, Freeman S, Freedman VH, Kaplan G. Effect of cytokine modulation by thalidomide on the gramomatous response inmurine tuberculosis.Tubercle Lung Disease, 1997,78(1):47-55.
40. Hodge DJ, Marino MW, Horton MR, Jungbluth A, Burdick MD, Strieter RM, Noble PW, Hunter CA, Puré E. Inhibition of interferon induced interleukin 12 production:a potential mechanism for the anti-inflammatory activities of tumor necrosis factor.PNAS,1998, 95(23):13806-13811.
41. Fenhalls G, Wong A, Bezuidenhout J, l van Helden P, Bardin P, Lukey PT. In situ production of gamma interferon,interleukin-4,and tumor necrosis factor alpha mRNA in human lung tuberculous granuloma.Infect Immun, 2000,68(5):2827-2836.
42. Gong J, Zhang M, Modlin R, Linsley PS, Iyer D, Lin Y, Barnes PF. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA4 expression. Infect Immun, 1996,64(3):913-918.
43. Rojas M, Olivier M, Gros P, Barrera LF, García LF. TNFα and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages.J. Immunol, 1999,162(10):6122-6131.
44. Ladel R, Miyajima A, Mee PJ, Tybulewicz VL, Murray R. Lethal tuberculosis in interleukin-6-deficient mutant mice.Blood,1996,88(7):2458-2464.
45. Reed JA, Ikegami M, Robb L, Begley CG, Ross G, Whitsett JA. Cytokine gene expression by cultures of human lymphocytes with autologous Mycobacterium tuberculosis-infected monocytes.AmJ Physiol Lung Cell Mol Physiol,2000,278(6):1164-1171.
46. Connell ND. Mycobacterium: isolation, maintenance, transformation, and mutant selection. Methods Cell Biol. 1994; (45):107–125.
47. Wayne,L.G,Sohaskey,C.D.Non-replicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol ,2001;55,139-163.
48. 戚中田.医学微生物学.北京:科学出版社, 2003.199-209.
49. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R, O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D. Neyrolles O, Gould K, Gares MP, Brett S, Janssen R,O'Gaora P, Herrmann JL, Prevost MC, Perret E, Thole JE, Young D. Lipoprotein access to MHC Class I presentation during infection of routine macrophages with live Mycobacteria. J Immun, 2001,166(1):447-457.
50. Couture M, Yeh SR, Wittenberg BA, Wittenberg JB, Ouellet Y, Rousseau DL, Guertin M. A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. PNAS, 1999, 96(20):11223-11228.
51. Weber I, Fritz C, Ruttkowski S, Kreft A, Bange FC. Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol, 2000,35(5):1017-1025.
52. 顾晓玲, 张红梅, 王洪海.结核分枝杆菌持续感染期分子机制的研究进展.中华结核和呼吸杂志,2005,28(1):47-49.
53. 江山.结核分枝杆菌潜伏性感染发生机制的研究进展.国外医学:微生物学分册,2003, 26(1):31-33.
54. Gatfield J, Pieters J. Essential role for cholesterol in entry of Mycobacteria into macrophages.Science,2000, 288(5471):1647-1650.
55. Pasula R,Wright JR, Kachel DL, Martin WJ. Surfactant protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis. J Clin Invest,1999,103(4):483-490.
56. Mahenthiralingam E, Marklund BI, Brooks LA, Smith DA, Bancroft GJ, Stokes RW. Site-Directed Mutagenesis of the 19-Kilodalton Lipoprotein Antigen Reveals No Essential Role for the Protein in the Growth and Virulence of Mycobacterium intracellulare. Infect Immun,1998,66(8):3626-3634.
57. Via LE, Deretic D, Ulmer RJ, Hibler NS, Huber LA, Deretic V. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between stages controlled by rab5 and rab7. J Biol Chem,1997,272(20):13326-13331.
58. Pieters J. Entry and survival of pathogenic mycobacteria in macrophages. Microbes Infect,2001,3(3):249-255.
59. Anand PK, Kaul D. Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages. FEMS Microbiol Lett,2005, 250(1):137-144.
60. Voss JJD, Rutter K, Schroeder BG, Barry CE. Iron Acquisition and Metabolism by Mycobacteria. J Bacteriol, 1999,181(15):4443-4451.
61. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol, 2001, 41(1):179-187.
62. Braunstein M, Espinosa BJ, Chan J, Belisle JT, Jacobs WR Jr. Braunstein M, Espinosa BJ, Chan J, Belisle JT, Jacobs Jr WR. SecA2 functions in the secretion of superoxide dismutase A and in the virulence of Mycobacterium tuberculosis. Mol Microbiol, 2003, 48(2):453-464.
63. Chan J, Kaufmann S. Immune mechanisms of protection in tuberculosis pathogenesis, protection and control. Bloom, B.R. Ed. American Society of Microbiology. 1994. Washington, D.C.9389-415.
64. Behr MA,Wilon MA,Gill WP,et al.Comparative genomics of BCG vaccines By whole genome DNA microarry.Science,1999;284:1520-1523.
65. Lewis KN, Liao R, Guinn KM,etal Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation.J Infect Dis. 2003 ;187(1):117-123.
66. Brandt L, Cunha JF, Olsen AW et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis [J]. Infect Immun. 2002, 70(5): 672–678.
67. Hubbard RD, Flory CM, FM Collins. Immunization of mice with mycobacterial culture filtrate proteins.Clin Exp Immunol, 1992,7(1):94-98.
68. Andersen P, Andersen AB, Sorensen AL, Nagai S. Recall of long-lived immunity to Mycobacterium tuberculosis infection in miceJ. Immunol, 1995,154(7):3359-3372.
69. Sonnenberg MG, Belisle JT. Definition of Mycobacterium tuberculosis culture filtrateproteins by two-dimensional polyacrylamide gel electrophoresis, N- terminal amino acid sequencing, and electrospray mass spectr- ometry.Infect Immun,1997,65(1):4515-4524.
70. Daudi cells analyzed by TCR gene transfer.J Immunol,1995;154(3):998-1006.
71. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in IFN-γ gene-disrupted mice.J Exp Med, 178(6):2243-2248.
72. Anderson P, Askgaard D, Gottschau A, Bennedsen J, Nagai S, Heron I. Identification of immunodominant antigens during infection with Mycobacterium tuberculosis. Scand J Immunol,1992;36(6):823-831.
73. Stenger S. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science,1998;282(5386):121-125.
74. Lowrie DB, Silva CL. Enhancement of immunocompetence in tuberculosis by DNA vaccination.Vaccine, 2000(18):1712-1716.
75. 范雄林, 李元, 徐志凯.结核分枝杆菌基因疫苗研究进展.细胞与分子免疫学杂志, 2001,17(4):121-123.
76. 师长宏. 融合表达 Ag85B-ESAT6 的增强型结核分枝杆菌疫苗研究. 第四军医大学博士论文. 2004 年.
77. Morris S, Kelley C, Howard A, et al. The immunogenicity of single and combination DNA vaccines against tuberculosis [J]. Vaccine, 2002, 18(1):2155-2163.
78. Kamath AT, Feng CG, Macdonald M, et al. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis [J].Infect Immun. 1999, 67(4):1702-1707.
79. Skinner MA, Ramsay AJ, Buchan GS, et al. A DNA prime live vaccine boost strategy in mice can augment IFN-gamma responsesto mycobacterial antigens but does not increase the p rotective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis [J]. Immunology. 2003,108(4):548-555
80. Orme IM. Current progress in tuberculosis vaccine development [J].Vaccine,2005, 23(4):2105-2108.
81. Dai W, Huang H, Yuan Y,etal .Novel vaccination strategies based on recombinant Mycobacterium bovis BCG.Int J Med Microbiol,2003 ;292 (7-8) :441-451.
82. Horwitz MA, Harth G, Dillon BJ, et al. Recombinant bacillus Calmette-Guerin (BCG) vaccined expressing the major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model [J]. Proc Natl Acad Sci USA. 2000,97(25):13853-13858.
83. Gedde MM,Higgins DE,Tilney LG,et al.Role of listeriolysin in cell-to-cell spread of Listeria monocytogenes.Infect Immun, 2000,68(2):999-1003.
84. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. Mycobacterium bovis Bacille Calmette Guerin strains secreting listeriolysin of Listeria monocytogenes. PNAS,1998,95(9):5299-5304.
85. Dhar N, Rao V, Tyagi AK,etal.Skewing of the Th1/Th2 responses in mice due to variation in the level of expression of an antigen in a recombinant BCG system..Immunol Lett, 2003;88(3):175-184.
86. Ghedrghiu M,Lagranderie MRR,Gicquel BME,et al.Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen.Infection Immunity,1994;62(10):4287-4295.
87. 胡佳杰, 文学明, 肖爱清等. 重组 M.S-Sj26GST 疫苗有关毒性实验研究[J]. 华南预防医学, 2002; 28(5):44-45.
88. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 11: 455–459.
89. 王永其. 对 MTB 涂片染色的评价. 临床肺科杂志. 2000;5:123-124.
90. 陆宇,朱莉贞,段连山. 结核分枝杆菌活菌检测方法及应用[J]. 中华结核和呼吸杂志. 2004;(6):423-425.
91. Gingeras TR. RNA reference materials for gene expression studies. Difficult first steps. Clin Chem. 2004; 50 (8): 289-1290.
92. Gilpin C, Abdelaal MA, Osoba AO. Rapid diagnosis of Mycobacterium tuberculosis by Amplicor PCR and LCR in a Clinical Laboratory. Ann Saudi Med. 1997 Sep; 17(5): 572-574.
93. Stocher M, Leb V, Berg I. A convenient approach to the generation of multiple internal control DNA for a panel of real-time PCR assays [J]. Virol Methods, 2003;108 (1):1-8.
94. Troesch A, Nguyen H, Miyada CG, Desvarenne S, Gingeras TR, Kaplan PM, Cros P, Mabilat C. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J Clin Microbiol. 1999; 37 (1): 49-55.
95. Wilson M, DeRisi J, Kristensen HH, Imboden P, Rane S, Brown PO, Schoolnik GK. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc Natl Acad Sci U S A. 1999;96 (22): 12833-12838.
96. Chan ED, Heifets I, Iseman MD.Immunogic diagnosis of tuberculosis: a Review [J]. Tubercle and Lung Disease. 2000; 80 (3):131-140.
97. 孔忠顺,管波清,古淑香,等. 血清抗脂阿拉伯甘露糖及 38KD 抗体检测对涂阴肺结核及肺外结核诊断价值[J]. 中国防痨杂志. 2002;24(3):140–142.
98. Menzies R, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. Am Rev Respir Dis.1992; 145:621–625.
99. 何俊瑛,黄庆生. 脑脊液单核细胞内结核抗原检测对结脑早期诊断的意义[J]. 脑与神经疾病杂志,2005,13(3):201-206.
100. Gangadharam PR. Mycobacterial dormancy. Tuber Lung Dis. 1995; 76 (6): 477-479.
101. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun. 1996;64 (6):2062-2069.
102. Wayne LG. Dormancy of Mycobacterium tuberculosis and latency of disease. Eur J ClinMicrobiol Infect Dis. 1994;13 (11):908-914.
103. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol.1998; 180 (4):801-808.
104. Hu YM, Butcher PD, Sole K, Mitchison DA, Coates AR. Protein synthesis isshutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett. 1998;158 (1):139-145.
105. Lim A, Eleuterio M, Hutter B, Murugasu-Oei B, Dick T. Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J Bacteriol.1999;(181):2252–2256.
106. Shleeva M, Mukamolova GV, Young M, et al. Formation of 'non-culturable' cells of Mycobacterium smegmatis in stationary phase in response to growth under suboptimal conditions and their Rpf-mediated resuscitation[J]. Microbiology. 2004;150(6): 1687- 97.
107. DeMaio J, Zhang Y, Ko C, Young DB, Bishai WR. A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1996;93 (7): 2790-2794.
108. Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK. AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors. 1999; 10 (2-3): 211-217.
109. Biketov S Biketov S, Mukamolova GV, Potapov V.Culturability of Mycobacterium tuberculosis cells isolated from murine macrophages:a bacterial growth factor promotes recovery. FEMS Immunol Med Microbiol, 2000,29(4):223-240.
110. Cohen-Gonsaud M , Keep N H , Davies A P , Ward J., Henderson B., Voloshin S A ; Kaprelyants A S. Voloshin S.A. , Kaprelyants A.S...Resuscitation-promoting factors possess a lysozyme-like domain [J ].Trends Biochem Sci,2004,29(1):7-10.
111. The structure of a resuscitation-promoting factor domain from Mycobacterium tuberculosis shows homology to lysozymes [J ].Nat Struct Mol Biol,2005,12(3):270-273.
112. Mukamolova G V , Murzin A G, Salina E G, Demina,G.R.,Kell,D.B.,Kaprelyants,A.S. Muralytic activity of Micrococcus luteus Rpf and its relationship to physiological activity in promoting bacterial growth and resuscitation [ J ] .Mol Microbiol , 2006,59(1):84-89.
113. Mukamolova GV,Turapov OA,Young DI,Kaprelyants AS, Kell DB and Young. ML A family of autocrine growth factors in Mycobacterium tuberculosis. Mol Microbiol 2002,46(3):623–635.
114. Tufariello JM.,Jacobs WR.Individual Mycobacterium tuberculosis resuscitation promoting factor homologues are dispensable for growth in vitro and in vivo. Infect. Immun. 2004;72:515–526
115. Zhu, G., H. Xiao, V. P. Mohan, K. Tanaka, S. Tyagi, F. Tsen, P. Salgame, and J. Chan.. Gene expression in the tuberculous granuloma: analysis by laser capture microdissection and real-time PCR. Cell. Microbiol. 2003;5:445–453.
116. Shleeva M, Mukamolova GV, Young M,et al.Formation of 'non-culturable' cells of Mycobacterium smegmatis in stationary phase in response to growth under suboptimal conditions and their Rpf-mediated resuscitation. Microbiology.2004;150(Pt 6):1687-97.
117. Vladimir V. Yeremeev, Tatiana K. Kondratieva, Elvira I. Rubakova, et al. Proteins of the Rpf Family: Immune Cell Reactivity and Vaccination Efficacy against Tuberculosis in Mice [J]. Infect Immun. 2003 August;71(8): 4789–4794.
118. Downing,K.J.,Mischenko,V.V.,Shleeva,M.O.,Young,D.I.,Young,M.,Kaprelyants,A.S.,Apt,A.S.,and Mizrahi,V. Mutants of Mycobacterium tuberculosis Lacking Three of the Five rpf-Like Genes Are Defective for Growth In Vivo and for Resuscitation In Vitro Infect Immun. 2005,73(5) 3038–3043
119. Downing KJ, Betts JC, Young DI, McAdam RA, Kelly F, Young M, Mizrahi V. Global expression profiling of strains harbouring null mutations reveals that the five rpf-like genes of Mycobacterium tuberculosis show functional redundancy. Tuberculosis (Edinb). 2004; 84 (3-4): 167-179.
120. Telkov MV, Demina GR, Voloshin SA, Salina EG, Dudik TV, Stekhanova TN, Mukamolova GV, Kazaryan KA, Goncharenko AV, Young M, Kaprelyants AS. Proteins of the Rpf (resuscitation promoting factor) family are peptidoglycan hydrolases. Biochemistry (Mosc). 2006;71 (4): 414-422.
121. 薛莹.结核分枝杆菌 Rpf 样蛋白生物学及免疫学活性的研究. 第四军医大学博士论文. 2005 年.
122. Fischer B, Sumner I.Isolation. Renaturation and formation of disulfide bonds of eukaryotic proteins expressed in E.coli as inclusion bodies [J]. Biotech Bioeng.1993,41(1):63-66.
123. Fang M, Huang HL.Advances in in vitro refolding of inclusion body proteins [J]. Sheng Wu Gong Cheng Xue Bao.2001,17(6):608-612.
124. 崇波.鼠源性 IgM 类单克隆抗俸的纯化方法. 单克隆抗体通讯 1992, 8(2): 77-79
125. 刘庆良,邵美琪.小鼠IgG类单克隆抗体 3 种纯化方法的比较.单克隆抗体通讯 1992, 8(3):54-56
126. Sgaya S, Fujita K, Kikuchi A, Ueda H, Takakuwa K, Kodama S, Tanaka K. Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther, 1996, 7(2): 223-230
127. 高辉,柏银兰,王丽梅等. 结核分枝杆菌 RpfA 蛋白的表达纯化与鉴定. 第四军医大学学报,2006;27(18):1633-1636.
128. Zhu XJ, Venkataprased N, Thangaraj HS, et al. Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis[J]. J Immunol, 1997;158: 5921-5926.
129. Zhang M ,Lin Y, Iyer DV, et al. T cell cytokine responses in human infection with Mycobacterium tuberculosis[J]. Infect Immun, 1995,63: 3231-3234.
130. Rojas M,Olivier M,Gros P,et al. TNFα and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages[J].J.Immunol,1999, 162:6122-6131.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |